ID   BMR1A_HUMAN             Reviewed;         532 AA.
AC   P36894; A8K6U9; Q8NEN8;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-MAR-2005, sequence version 2.
DT   10-MAY-2017, entry version 204.
DE   RecName: Full=Bone morphogenetic protein receptor type-1A;
DE            Short=BMP type-1A receptor;
DE            Short=BMPR-1A;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin receptor-like kinase 3;
DE            Short=ALK-3;
DE   AltName: Full=Serine/threonine-protein kinase receptor R5;
DE            Short=SKR5;
DE   AltName: CD_antigen=CD292;
DE   Flags: Precursor;
GN   Name=BMPR1A; Synonyms=ACVRLK3, ALK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-2.
RC   TISSUE=Placenta;
RX   PubMed=8397373;
RA   ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J.,
RA   Toyoshima H., Heldin C.-H., Miyazono K.;
RT   "Activin receptor-like kinases: a novel subclass of cell-surface
RT   receptors with predicted serine/threonine kinase activity.";
RL   Oncogene 8:2879-2887(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-2.
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INTERACTION WITH BMP2, AND MUTAGENESIS OF 107-ASP--GLN-109.
RX   PubMed=22799562; DOI=10.1021/bi300942x;
RA   Mahlawat P., Ilangovan U., Biswas T., Sun L.Z., Hinck A.P.;
RT   "Structure of the Alk1 extracellular domain and characterization of
RT   its bone morphogenetic protein (BMP) binding properties.";
RL   Biochemistry 51:6328-6341(2012).
RN   [5]
RP   INTERACTION WITH GDF5.
RX   PubMed=24098149; DOI=10.1371/journal.pgen.1003846;
RA   Degenkolbe E., Konig J., Zimmer J., Walther M., Reissner C.,
RA   Nickel J., Ploger F., Raspopovic J., Sharpe J., Dathe K., Hecht J.T.,
RA   Mundlos S., Doelken S.C., Seemann P.;
RT   "A GDF5 point mutation strikes twice--causing BDA1 and SYNS2.";
RL   PLoS Genet. 9:E1003846-E1003846(2013).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 55-143 IN COMPLEX WITH BMP2,
RP   DISULFIDE BOND, AND INTERACTION WITH BMP2.
RX   PubMed=10881198; DOI=10.1038/75903;
RA   Kirsch T., Sebald W., Dreyer M.K.;
RT   "Crystal structure of the BMP-2-BRIA ectodomain complex.";
RL   Nat. Struct. Biol. 7:492-496(2000).
RN   [7]
RP   DISEASE.
RX   PubMed=11381269; DOI=10.1038/88919;
RA   Howe J.R., Bair J.L., Sayed M.G., Anderson M.E., Mitros F.A.,
RA   Petersen G.M., Velculescu V.E., Traverso G., Vogelstein B.;
RT   "Germline mutations of the gene encoding bone morphogenetic protein
RT   receptor 1A in juvenile polyposis.";
RL   Nat. Genet. 28:184-187(2001).
RN   [8]
RP   STRUCTURE BY NMR OF 51-152, DISULFIDE BONDS, AND INTERACTION WITH
RP   BMP2.
RX   PubMed=18937504; DOI=10.1021/bi801059j;
RA   Klages J., Kotzsch A., Coles M., Sebald W., Nickel J., Muller T.,
RA   Kessler H.;
RT   "The solution structure of BMPR-IA reveals a local disorder-to-order
RT   transition upon BMP-2 binding.";
RL   Biochemistry 47:11930-11939(2008).
RN   [9]
RP   VARIANTS JPS ARG-124; ASP-338 AND TYR-376.
RX   PubMed=11536076; DOI=10.1086/323703;
RA   Zhou X.-P., Woodford-Richens K., Lehtonen R., Kurose K., Aldred M.,
RA   Hampel H., Launonen V., Virta S., Pilarski R., Salovaara R.,
RA   Bodmer W.F., Conrad B.A., Dunlop M., Hodgson S.V., Iwama T.,
RA   Jaervinen H., Kellokumpu I., Kim J.C., Leggett B., Markie D.,
RA   Mecklin J.-P., Neale K., Phillips R., Piris J., Rozen P.,
RA   Houlston R.S., Aaltonen L.A., Tomlinson I.P.M., Eng C.;
RT   "Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile
RT   polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba
RT   syndromes.";
RL   Am. J. Hum. Genet. 69:704-711(2001).
RN   [10]
RP   VARIANTS JPS ASP-62; TYR-82 AND CYS-443.
RX   PubMed=12417513; DOI=10.1007/BF02557528;
RA   Sayed M.G., Ahmed A.F., Ringold J.R., Anderson M.E., Bair J.L.,
RA   Mitros F.A., Lynch H.T., Tinley S.T., Petersen G.M., Giardiello F.M.,
RA   Vogelstein B., Howe J.R.;
RT   "Germline SMAD4 or BMPR1A mutations and phenotype of juvenile
RT   polyposis.";
RL   Ann. Surg. Oncol. 9:901-906(2002).
RN   [11]
RP   VARIANT JPS ARG-130.
RX   PubMed=12136244; DOI=10.1007/s00439-002-0748-9;
RA   Friedl W., Uhlhaas S., Schulmann K., Stolte M., Loff S., Back W.,
RA   Mangold E., Stern M., Knaebel H.P., Sutter C., Weber R.G.,
RA   Pistorius S., Burger B., Propping P.;
RT   "Juvenile polyposis: massive gastric polyposis is more common in MADH4
RT   mutation carriers than in BMPR1A mutation carriers.";
RL   Hum. Genet. 111:108-111(2002).
RN   [12]
RP   VARIANT JPS THR-470.
RX   PubMed=12630959; DOI=10.1034/j.1399-0004.2003.00008.x;
RA   Kim I.J., Park J.H., Kang H.C., Kim K.H., Kim J.H., Ku J.L.,
RA   Kang S.B., Park S.Y., Lee J.S., Park J.G.;
RT   "Identification of a novel BMPR1A germline mutation in a Korean
RT   juvenile polyposis patient without SMAD4 mutation.";
RL   Clin. Genet. 63:126-130(2003).
RN   [13]
RP   INVOLVEMENT IN JUVENILE POLYPOSIS OF INFANCY.
RX   PubMed=16685657; DOI=10.1086/504301;
RA   Delnatte C., Sanlaville D., Mougenot J.-F., Vermeesch J.-R.,
RA   Houdayer C., Blois M.-C., Genevieve D., Goulet O., Fryns J.-P.,
RA   Jaubert F., Vekemans M., Lyonnet S., Romana S., Eng C.,
RA   Stoppa-Lyonnet D.;
RT   "Contiguous gene deletion within chromosome arm 10q is associated with
RT   juvenile polyposis of infancy, reflecting cooperation between the
RT   BMPR1A and PTEN tumor-suppressor genes.";
RL   Am. J. Hum. Genet. 78:1066-1074(2006).
RN   [14]
RP   INVOLVEMENT IN HEREDITARY MIXED POLYPOSIS SYNDROME 2.
RX   PubMed=16525031; DOI=10.1136/jmg.2005.034827;
RA   Cao X., Eu K.W., Kumarasinghe M.P., Li H.H., Loi C., Cheah P.Y.;
RT   "Mapping of hereditary mixed polyposis syndrome (HMPS) to chromosome
RT   10q23 by genomewide high-density single nucleotide polymorphism (SNP)
RT   scan and identification of BMPR1A loss of function.";
RL   J. Med. Genet. 43:E13-E13(2006).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-2; TYR-58; CYS-443; MET-450 AND
RP   GLN-486.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [16]
RP   VARIANT THR-460.
RX   PubMed=25860647; DOI=10.1007/s10689-015-9803-2;
RA   Hansen M.F., Johansen J., Bjoernevoll I., Sylvander A.E.,
RA   Steinsbekk K.S., Saetrom P., Sandvik A.K., Drabloes F., Sjursen W.;
RT   "A novel POLE mutation associated with cancers of colon, pancreas,
RT   ovaries and small intestine.";
RL   Fam. Cancer 14:437-448(2015).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting
CC       of two type II and two type I transmembrane serine/threonine
CC       kinases. Type II receptors phosphorylate and activate type I
CC       receptors which autophosphorylate, then bind and activate SMAD
CC       transcriptional regulators. Receptor for BMP2, BMP4, GDF5 and
CC       GDF6. Positively regulates chondrocyte differentiation through
CC       GDF5 interaction. Mediates induction of adipogenesis by GDF6.
CC       {ECO:0000250|UniProtKB:P36895}.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Interacts with BMP2 (PubMed:10881198, PubMed:18937504).
CC       Interacts with low affinity with GDF5; positively regulates
CC       chondrocyte differentiation (PubMed:24098149).
CC       {ECO:0000269|PubMed:10881198, ECO:0000269|PubMed:18937504,
CC       ECO:0000269|PubMed:24098149}.
CC   -!- INTERACTION:
CC       P12643:BMP2; NbExp=11; IntAct=EBI-1029237, EBI-1029262;
CC       P12644:BMP4; NbExp=2; IntAct=EBI-1029237, EBI-1998134;
CC       P43026:GDF5; NbExp=3; IntAct=EBI-1029237, EBI-8571476;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Highly expressed in skeletal muscle.
CC   -!- DISEASE: Juvenile polyposis syndrome (JPS) [MIM:174900]: Autosomal
CC       dominant gastrointestinal hamartomatous polyposis syndrome in
CC       which patients are at risk for developing gastrointestinal
CC       cancers. The lesions are typified by a smooth histological
CC       appearance, predominant stroma, cystic spaces and lack of a smooth
CC       muscle core. Multiple juvenile polyps usually occur in a number of
CC       Mendelian disorders. Sometimes, these polyps occur without
CC       associated features as in JPS; here, polyps tend to occur in the
CC       large bowel and are associated with an increased risk of colon and
CC       other gastrointestinal cancers. {ECO:0000269|PubMed:11536076,
CC       ECO:0000269|PubMed:12136244, ECO:0000269|PubMed:12417513,
CC       ECO:0000269|PubMed:12630959}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Polyposis syndrome, mixed hereditary 2 (HMPS2)
CC       [MIM:610069]: A disease is characterized by atypical juvenile
CC       polyps, colonic adenomas, and colorectal carcinomas. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A
CC       and PTEN is a cause of chromosome 10q23 deletion syndrome, which
CC       shows overlapping features of the following three disorders:
CC       Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis
CC       syndrome. {ECO:0000269|PubMed:11381269,
CC       ECO:0000269|PubMed:16525031}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z22535; CAA80257.1; -; mRNA.
DR   EMBL; AK291764; BAF84453.1; -; mRNA.
DR   EMBL; BC028383; AAH28383.1; -; mRNA.
DR   CCDS; CCDS7378.1; -.
DR   PIR; I37163; I37163.
DR   RefSeq; NP_004320.2; NM_004329.2.
DR   RefSeq; XP_011538405.1; XM_011540103.2.
DR   RefSeq; XP_011538406.1; XM_011540104.2.
DR   UniGene; Hs.524477; -.
DR   PDB; 1ES7; X-ray; 2.90 A; B/D=55-143.
DR   PDB; 1REW; X-ray; 1.86 A; C/D=24-152.
DR   PDB; 2GOO; X-ray; 2.20 A; B/E=24-152.
DR   PDB; 2H62; X-ray; 1.85 A; C=24-152.
DR   PDB; 2H64; X-ray; 1.92 A; B=24-152.
DR   PDB; 2K3G; NMR; -; A=51-152.
DR   PDB; 2QJ9; X-ray; 2.44 A; C/D=24-152.
DR   PDB; 2QJA; X-ray; 2.60 A; C/D=24-152.
DR   PDB; 2QJB; X-ray; 2.50 A; C/D=24-152.
DR   PDB; 3NH7; X-ray; 2.70 A; A/B/C/D=24-152.
DR   PDB; 3QB4; X-ray; 2.28 A; B/D=24-152.
DR   PDBsum; 1ES7; -.
DR   PDBsum; 1REW; -.
DR   PDBsum; 2GOO; -.
DR   PDBsum; 2H62; -.
DR   PDBsum; 2H64; -.
DR   PDBsum; 2K3G; -.
DR   PDBsum; 2QJ9; -.
DR   PDBsum; 2QJA; -.
DR   PDBsum; 2QJB; -.
DR   PDBsum; 3NH7; -.
DR   PDBsum; 3QB4; -.
DR   ProteinModelPortal; P36894; -.
DR   SMR; P36894; -.
DR   BioGrid; 107125; 65.
DR   DIP; DIP-5793N; -.
DR   IntAct; P36894; 30.
DR   MINT; MINT-124304; -.
DR   STRING; 9606.ENSP00000224764; -.
DR   BindingDB; P36894; -.
DR   ChEMBL; CHEMBL5275; -.
DR   GuidetoPHARMACOLOGY; 1786; -.
DR   iPTMnet; P36894; -.
DR   PhosphoSitePlus; P36894; -.
DR   BioMuta; BMPR1A; -.
DR   DMDM; 61252444; -.
DR   EPD; P36894; -.
DR   MaxQB; P36894; -.
DR   PaxDb; P36894; -.
DR   PeptideAtlas; P36894; -.
DR   PRIDE; P36894; -.
DR   DNASU; 657; -.
DR   Ensembl; ENST00000372037; ENSP00000361107; ENSG00000107779.
DR   Ensembl; ENST00000635816; ENSP00000489707; ENSG00000107779.
DR   Ensembl; ENST00000636056; ENSP00000490273; ENSG00000107779.
DR   GeneID; 657; -.
DR   KEGG; hsa:657; -.
DR   UCSC; uc001kdy.4; human.
DR   CTD; 657; -.
DR   DisGeNET; 657; -.
DR   GeneCards; BMPR1A; -.
DR   GeneReviews; BMPR1A; -.
DR   HGNC; HGNC:1076; BMPR1A.
DR   HPA; CAB019398; -.
DR   MalaCards; BMPR1A; -.
DR   MIM; 174900; phenotype.
DR   MIM; 601299; gene.
DR   MIM; 610069; phenotype.
DR   MIM; 612242; phenotype.
DR   neXtProt; NX_P36894; -.
DR   OpenTargets; ENSG00000107779; -.
DR   Orphanet; 329971; Generalized juvenile polyposis/juvenile polyposis coli.
DR   Orphanet; 157794; Hereditary mixed polyposis syndrome.
DR   Orphanet; 144; Hereditary nonpolyposis colon cancer.
DR   Orphanet; 79076; Juvenile polyposis of infancy.
DR   PharmGKB; PA25386; -.
DR   eggNOG; KOG2052; Eukaryota.
DR   eggNOG; ENOG410XQT0; LUCA.
DR   GeneTree; ENSGT00760000118876; -.
DR   HOGENOM; HOG000230587; -.
DR   HOVERGEN; HBG054502; -.
DR   InParanoid; P36894; -.
DR   KO; K04673; -.
DR   OMA; KHYCKSM; -.
DR   OrthoDB; EOG091G0BIU; -.
DR   PhylomeDB; P36894; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-201451; Signaling by BMP.
DR   SignaLink; P36894; -.
DR   SIGNOR; P36894; -.
DR   ChiTaRS; BMPR1A; human.
DR   EvolutionaryTrace; P36894; -.
DR   GeneWiki; BMPR1A; -.
DR   GenomeRNAi; 657; -.
DR   PRO; PR:P36894; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000107779; -.
DR   CleanEx; HS_BMPR1A; -.
DR   ExpressionAtlas; P36894; baseline and differential.
DR   Genevisible; P36894; HS.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:1990712; C:HFE-transferrin receptor complex; IC:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC.
DR   GO; GO:0098821; F:BMP receptor activity; ISS:UniProtKB.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IEA:InterPro.
DR   GO; GO:0046332; F:SMAD binding; IDA:HGNC.
DR   GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0061312; P:BMP signaling pathway involved in heart development; IC:BHF-UCL.
DR   GO; GO:0003161; P:cardiac conduction system development; ISS:BHF-UCL.
DR   GO; GO:0003215; P:cardiac right ventricle morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL.
DR   GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0048589; P:developmental growth; IEA:Ensembl.
DR   GO; GO:0035912; P:dorsal aorta morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0009950; P:dorsal/ventral axis specification; IEA:Ensembl.
DR   GO; GO:0007398; P:ectoderm development; IEA:Ensembl.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0048568; P:embryonic organ development; IEA:Ensembl.
DR   GO; GO:0003272; P:endocardial cushion formation; ISS:BHF-UCL.
DR   GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL.
DR   GO; GO:1905285; P:fibrous ring of heart morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060914; P:heart formation; IEA:Ensembl.
DR   GO; GO:0035137; P:hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; IMP:BHF-UCL.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0048368; P:lateral mesoderm development; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0048382; P:mesendoderm development; IEA:Ensembl.
DR   GO; GO:0001707; P:mesoderm formation; IEA:Ensembl.
DR   GO; GO:0003183; P:mitral valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001880; P:Mullerian duct regression; IEA:Ensembl.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; IEA:Ensembl.
DR   GO; GO:0014912; P:negative regulation of smooth muscle cell migration; IMP:BHF-UCL.
DR   GO; GO:0014032; P:neural crest cell development; IEA:Ensembl.
DR   GO; GO:0021998; P:neural plate mediolateral regionalization; IEA:Ensembl.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060021; P:palate development; IEA:Ensembl.
DR   GO; GO:0048352; P:paraxial mesoderm structural organization; IEA:Ensembl.
DR   GO; GO:0061626; P:pharyngeal arch artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0021983; P:pituitary gland development; IEA:Ensembl.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:BHF-UCL.
DR   GO; GO:1904414; P:positive regulation of cardiac ventricle development; ISS:BHF-UCL.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:1902895; P:positive regulation of pri-miRNA transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0060391; P:positive regulation of SMAD protein import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:1904707; P:positive regulation of vascular smooth muscle cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:HGNC.
DR   GO; GO:0060043; P:regulation of cardiac muscle cell proliferation; ISS:BHF-UCL.
DR   GO; GO:2000772; P:regulation of cellular senescence; IEA:Ensembl.
DR   GO; GO:0048378; P:regulation of lateral mesodermal cell fate specification; IEA:Ensembl.
DR   GO; GO:0001756; P:somitogenesis; IEA:Ensembl.
DR   GO; GO:0019827; P:stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0003186; P:tricuspid valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003223; P:ventricular compact myocardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; ISS:BHF-UCL.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR003605; GS_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   SMART; SM00467; GS; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Complete proteome; Disease mutation;
KW   Disulfide bond; Glycoprotein; Kinase; Magnesium; Manganese; Membrane;
KW   Metal-binding; Nucleotide-binding; Polymorphism; Receptor;
KW   Reference proteome; Serine/threonine-protein kinase; Signal;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24    532       Bone morphogenetic protein receptor type-
FT                                1A.
FT                                /FTId=PRO_0000024410.
FT   TOPO_DOM     24    152       Extracellular. {ECO:0000255}.
FT   TRANSMEM    153    176       Helical. {ECO:0000255}.
FT   TOPO_DOM    177    532       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      204    233       GS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00585}.
FT   DOMAIN      234    525       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     240    248       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      107    109       Mediates specificity for BMP ligand.
FT   ACT_SITE    362    362       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     261    261       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   CARBOHYD     73     73       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     61     82       {ECO:0000269|PubMed:10881198,
FT                                ECO:0000269|PubMed:18937504}.
FT   DISULFID     63     67       {ECO:0000269|PubMed:10881198,
FT                                ECO:0000269|PubMed:18937504}.
FT   DISULFID     76    100       {ECO:0000269|PubMed:10881198,
FT                                ECO:0000269|PubMed:18937504}.
FT   DISULFID    110    124       {ECO:0000269|PubMed:10881198,
FT                                ECO:0000269|PubMed:18937504}.
FT   DISULFID    125    130       {ECO:0000269|PubMed:10881198,
FT                                ECO:0000269|PubMed:18937504}.
FT   VARIANT       2      2       P -> T (in dbSNP:rs11528010).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8397373}.
FT                                /FTId=VAR_041397.
FT   VARIANT      58     58       F -> Y (in a renal clear cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041398.
FT   VARIANT      62     62       Y -> D (in JPS).
FT                                {ECO:0000269|PubMed:12417513}.
FT                                /FTId=VAR_022828.
FT   VARIANT      82     82       C -> Y (in JPS).
FT                                {ECO:0000269|PubMed:12417513}.
FT                                /FTId=VAR_022829.
FT   VARIANT     124    124       C -> R (in JPS; dbSNP:rs199476087).
FT                                {ECO:0000269|PubMed:11536076}.
FT                                /FTId=VAR_015533.
FT   VARIANT     130    130       C -> R (in JPS).
FT                                {ECO:0000269|PubMed:12136244}.
FT                                /FTId=VAR_022830.
FT   VARIANT     338    338       A -> D (in JPS; dbSNP:rs199476086).
FT                                {ECO:0000269|PubMed:11536076}.
FT                                /FTId=VAR_015534.
FT   VARIANT     376    376       C -> Y (in JPS; dbSNP:rs199476088).
FT                                {ECO:0000269|PubMed:11536076}.
FT                                /FTId=VAR_015535.
FT   VARIANT     443    443       R -> C (in JPS; dbSNP:rs35619497).
FT                                {ECO:0000269|PubMed:12417513,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_022831.
FT   VARIANT     450    450       V -> M (in dbSNP:rs55932635).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041399.
FT   VARIANT     460    460       M -> T (found in a patient with tubular
FT                                adenoma and rectal neuroendocrine tumor;
FT                                unknown pathological significance;
FT                                dbSNP:rs758309022).
FT                                {ECO:0000269|PubMed:25860647}.
FT                                /FTId=VAR_077353.
FT   VARIANT     470    470       M -> T (in JPS; dbSNP:rs199476089).
FT                                {ECO:0000269|PubMed:12630959}.
FT                                /FTId=VAR_022832.
FT   VARIANT     486    486       R -> Q (in a gastric adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs752802257).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041400.
FT   MUTAGEN     107    109       DFQ->REL: Affinity for BMP2 decreased by
FT                                over 200-fold.
FT                                {ECO:0000269|PubMed:22799562}.
FT   STRAND       59     62       {ECO:0000244|PDB:2H62}.
FT   STRAND       64     66       {ECO:0000244|PDB:2H62}.
FT   STRAND       75     88       {ECO:0000244|PDB:2H62}.
FT   STRAND       90     92       {ECO:0000244|PDB:2H62}.
FT   STRAND       94    101       {ECO:0000244|PDB:2H62}.
FT   HELIX       106    111       {ECO:0000244|PDB:2H62}.
FT   STRAND      116    118       {ECO:0000244|PDB:2QJA}.
FT   STRAND      120    125       {ECO:0000244|PDB:2H62}.
FT   HELIX       130    133       {ECO:0000244|PDB:2H62}.
SQ   SEQUENCE   532 AA;  60198 MW;  00CE2DDDA3A44170 CRC64;
     MPQLYIYIRL LGAYLFIISR VQGQNLDSML HGTGMKSDSD QKKSENGVTL APEDTLPFLK
     CYCSGHCPDD AINNTCITNG HCFAIIEEDD QGETTLASGC MKYEGSDFQC KDSPKAQLRR
     TIECCRTNLC NQYLQPTLPP VVIGPFFDGS IRWLVLLISM AVCIIAMIIF SSCFCYKHYC
     KSISSRRRYN RDLEQDEAFI PVGESLKDLI DQSQSSGSGS GLPLLVQRTI AKQIQMVRQV
     GKGRYGEVWM GKWRGEKVAV KVFFTTEEAS WFRETEIYQT VLMRHENILG FIAADIKGTG
     SWTQLYLITD YHENGSLYDF LKCATLDTRA LLKLAYSAAC GLCHLHTEIY GTQGKPAIAH
     RDLKSKNILI KKNGSCCIAD LGLAVKFNSD TNEVDVPLNT RVGTKRYMAP EVLDESLNKN
     HFQPYIMADI YSFGLIIWEM ARRCITGGIV EEYQLPYYNM VPSDPSYEDM REVVCVKRLR
     PIVSNRWNSD ECLRAVLKLM SECWAHNPAS RLTALRIKKT LAKMVESQDV KI
//
